Dianthus TherapeuticsvsJohnson & Johnson

DNTH and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

DNTH

Dianthus Therapeutics, Inc.

$84.55

Value $4.8B

-0.33%
DNTH's page

Dianthus Therapeutics (DNTH) has a market value of $4.8B and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, DNTH moved +107.3% and JNJ +36.6%. Dividend yield: DNTH none, JNJ 1.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    DNTH$4.8B

    JNJ$652B

    JNJ is 137 times DNTH

  • Revenue, 12 months

    DNTH$2.0M

    JNJ$99.3B

    JNJ is 48,789 times DNTH

  • Net income, 12 months

    DNTH-$202M

    JNJ$16.1B

  • Operating margin

    DNTH-11,592.7%

    JNJ–

  • ROIC

    DNTH-20.0%

    JNJ12.4%

    32.4 points apart

  • P/E

    DNTH–

    JNJ40.5

  • Dividend yield

    DNTH0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    DNTH-21.0%

    JNJ+90.9%

    111.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

DNTH-21.0%

JNJ+90.9%

010020020222023202420252026
Returns by period
PeriodDNTHWith dividendsJNJWith dividends
1 year since November 19, 2025+107.3%Price +107.3%+36.6%Price +33.6%
3 years since November 20, 2023+627.6%+93.8% a yearPrice +627.6%+94.9%+24.9% a yearPrice +80.4%
5 years since November 19, 2021-21.0%-4.6% a yearPrice -21.0%+90.9%+13.8% a yearPrice +66.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

DNTHDianthus TherapeuticsJNJJohnson & Johnson

Valuation

DNTHJNJ
Valuation
Price$84.55$270.47
Market value$4.8B$652B
Enterprise value (EV)$3.9B$679B
P/E–40.5
P/E, 5-year median–21.9
P/B3.88.0
EV/EBIT–38.3
Free cash flow yield–3.2%

Results and growth

DNTHJNJ
Results and growth
Revenue, 12 months$2.0M$99.3B
Net income, 12 months-$202M$16.1B
Free cash flow, 12 months-$176M$20.6B
Earnings per share, 12 months-$4.08$6.59
Revenue growth, year on year-67.4%6.1%
Revenue growth a year, past-15.1%over 2 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

DNTHJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin-11,592.7%–
Net margin-7,973.3%16.2%
ROIC-20.0%12.4%
ROE-21.7%19.7%

Balance sheet

DNTHJNJ
Balance sheet
Cash$838M$17.2B
Total debt$1.2M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

DNTHJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: DNTH or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Dianthus Therapeutics or Johnson & Johnson?

By market value, Johnson & Johnson ($652B) is about 136.9 times Dianthus Therapeutics ($4.8B), at today's prices.

How did DNTH and JNJ stock do over the last 5 years?

Since November 19, 2021, DNTH's price moved -21.0% and JNJ's +66.0%. With dividends: DNTH -21.0% (-4.6% a year), JNJ +90.9% (+13.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, DNTH or JNJ?

The dividend yield at today's price is none for Dianthus Therapeutics and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Dianthus Therapeutics or Johnson & Johnson?

Over the last twelve months, the net margin was -7,973.3% for Dianthus Therapeutics and 16.2% for Johnson & Johnson, and the operating margin -11,592.7% and –. Revenue was $2.0M and $99.3B.

Which is the better investment, Dianthus Therapeutics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.